
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531
Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular Dystrophy (DMD), WVE-N531, has met all trial endpoints, showing the drug led to significant improvements in muscle health. Results …